ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Eyenovia, Betaliq Will Have Combined C
Pink SheetThe UK’s originator drugs and generics industries are at odds over a rise in the clawbacks that companies must pay the government on the sales of branded medicines to the National Health Service under
ScripEdward Kaye is stepping down as CEO of Stoke Therapeutics, just weeks after securing a vital deal with Biogen on its late-stage Dravet syndrome candidate, zorevunersen. The announcement of Kaye’s depa
ScripDespite notable advancements in Alzheimer’s disease treatment during the last five years, the therapeutic area remains a complex and uncertain area for drug developers. Approvals for the first disease